Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors

Francesca Spada, Lorenzo Antonuzzo, Riccardo Marconcini, Davide Radice, Andrea Antonuzzo, Sergio Ricci, Francesco Di Costanzo, Annalisa Fontana, Fabio Gelsomino, Gabriele Luppi, Elisabetta Nobili, Salvatore Galdy, Chiara Alessandra Cella, Angelica Maria Sonzogni, Eleonora Pisa, Massimo Barberis, Nicola Fazio

Research output: Contribution to journalArticlepeer-review


Purpose: The role of chemotherapy in low/intermediate grade neuroendocrine tumors (NETs) is still debated. We present the results of an Italian multicenter retrospective study, evaluating activity and toxicity of oxaliplatin-based chemotherapy in patients with advanced NETs. Methods: Clinical records from 5 referral centers were reviewed. Disease control rate (DCR) corresponding to PR+SD (partial response + stable disease) at 6 months, progression free survival (PFS), overall survival (OS) and toxicity were calculated. Ki67 labeling-index, grade of differentiation and excision-repair-cross-complementing group-1 (ERCC-1) were analyzed in tissue tumor samples. Results: Seventy-eight patients entered the study. Primary sites were: pancreas in 46, gastrointestinal in 24, lung in 19, and unknown in 10% patients. The vast majority were G2 (2010 WHO classification). Eighty-six percent of patients were metastatic, 87% pretreated and progressive to previous therapies. 65% patients received capecitabine/oxaliplatin (CAPOX), 6% gemcitabine/oxaliplatin (GEMOX), 29% leucovorin/fluorouracil/oxaliplatin (FOLFOX-6). Partial response occurred in 26% patients, half of them with pancreatic NETs (PNETs), and SD in 54%. With 21 months median follow-up, the median PFS and OS were 8 and 32 months with 70 and 45 events, respectively. The most frequent G3 toxicities were neurological and gastrointestinal. ERCC-1 immunohistochemical over-expression was positive in 4/28 evaluated samples, with no significant correlation with clinical outcome. Conclusion: This analysis suggests that oxaliplatin-based chemotherapy can be active with a manageable safety profile in advanced NETs irrespective of the primary sites and tumor grade. The 80% DCR and 8 months PFS could justify a prospective study in NETs with intermediate biological characteristics, especially with pancreatic primary. © 2016 S. Karger AG, Basel

Original languageEnglish
Publication statusAccepted/In press - Jan 21 2016

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Endocrine and Autonomic Systems
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors'. Together they form a unique fingerprint.

Cite this